HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Sanofi Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Sanofi Intelligence Report

Generated from 16 signals · 5 evidence sources

Type

Company Intelligence Report

Generated

Aug 5, 2026

Confidence

Moderate Confidence · 69%

Evidence

82 items

Sources

28

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Sanofi maintains an active intelligence profile across Diabetes, Insulin, Cardiovascular, Antihypertensive, Cardiology. 16 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 69% across 5 tracked sources. Highest-priority development: FDA Approves Supplemental Application for SARCLISA (Isatuximab-IRFC). Portfolio development. FDA Approves Supplemental Application for SARCLISA (Isatuximab-IRFC) is an owned Sanofi portfolio development in Oncology · Monoclonal Antibody.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. portfolio

    FDA Approves Supplemental Application for SARCLISA (Isatuximab-IRFC)

    FDA approval

    View detail
  2. regulatory

    Pratik Doshi, M.D. / Alembic Pharmaceuticals Ltd. - 731020 - 07/10/2026

    Regulatory precedent may inform portfolio positioning

    View detail
  3. regulatory

    Centaur Pharmaceuticals Private Ltd. - 651080 - 06/05/2023

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    Centaur Pharmaceuticals Private Ltd. - 651080 - 12/03/2025

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    Form FDA 3674 - Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    Form FDA 3674 - Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    IND Application Reporting: IND Safety Reports

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    Investigational New Drug (IND) Application

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    FDA AP — AVAPRO (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  11. regulatory

    FDA AP — AVAPRO (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  12. regulatory

    FDA AP — BAXFENDY (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 1409 with buyer quality 10 (Enterprise). Competitive pressure: Low. Portfolio impact: High.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA Approves Supplemental Application for SARCLISA (Isatuximab-IRFC)

    Low Confidence · 0%

    FDA approval

    Source: Humanexa Signals, FDA, Portfolio

    View evidence

  • Pratik Doshi, M.D. / Alembic Pharmaceuticals Ltd. - 731020 - 07/10/2026

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Centaur Pharmaceuticals Private Ltd. - 651080 - 06/05/2023

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Centaur Pharmaceuticals Private Ltd. - 651080 - 12/03/2025

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Form FDA 3674 - Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Form FDA 3674 - Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • IND Application Reporting: IND Safety Reports

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Investigational New Drug (IND) Application

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — AVAPRO (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — AVAPRO (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — BAXFENDY (ORIG)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension

    Low Confidence · 54%

    Regulatory precedent may inform portfolio positioning

    Source: MHRA, MHRA, Regunera

    View evidence

  • FDA Accepts First In Silico Drug Development Tool Under ISTAND Program to Help Predict Drug-Induced Liver Injury

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — AVAPRO (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Other | Cancer Accelerated Approvals

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA grants supplemental application approval for Dupixent (BLA761055)

    Immunology · IL-4/IL-13

  • Sanofi's Venglustat Phase 3 Trial Targets Left Ventricular Mass in Fabry Disease

    Cardiology · Fabry Disease

  • FDA Accepts Supplemental NDA for AVAPRO by Sanofi

    Cardiology · Antihypertensive

  • Isatuximab Evaluated in Stem Cell Transplant for Multiple Myeloma and Lymphoma

    Hematology · Multiple Myeloma

  • FDA Accepts Application for SARCLISA (Isatuximab-IRFC) by Sanofi

    Oncology · Monoclonal Antibody

  • FDA Approves Supplemental Application for SARCLISA (Isatuximab-IRFC)

    Oncology · Monoclonal Antibody

  • FDA Accepts Supplement for SARCLISA (Isatuximab-IRFC) by Sanofi

    Oncology · Monoclonal Antibody

  • Sanofi's Nirsevimab Study to Assess RSV Immunisation Rates in Queensland Infants

    Infectious Disease · Respiratory Syncytial Virus (RSV)

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.